PRR5L

Across TCGA pan-cancer cohorts, PRR5L Mutation is linked to patient survival in 5 of 34 cancer types, making it a survival-associated PRR5L data layer compared with 22 for mass-spec protein and 3 for mass-spec protein.

The strongest signal is observed in cervical squamous cell carcinoma and endocervical adenocarcinoma (CESC), where higher PRR5L Mutation is associated with worse overall survival. In most high-consensus cancer types, elevated PRR5L expression acts as an unfavorable survival marker, although some lineages such as STAD show a favorable association.

CESC, LUAD, and PRAD are the cancer types where PRR5L Mutation most reproducibly stratifies survival.

Mutation survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
CESC	OS	Median	IV	0.091	0.593	<.001	12	view →
LUAD	OS	Median	III,IV	0.223	0.677	.006	9	view →
PRAD	DFS	Median	All	0.085	0.774	<.001	6	view →
STAD	OS	Median	III,IV	0.851	0.307	.038	3	view →
SKCM	OS	Median	III,IV	0.230	0.721	.004	3	view →

Pink = unfavorable, green = favorable. Showing the 5 strongest of 5 lineages.

PRR5L–CESC (OS)

Open the CESC breakdown →